查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088944

免疫調節劑市場：2026-2032年全球市場預測（依產品類型、給藥途徑、適應症、年齡層、通路及最終用戶分類）

Immunomodulators Market by Product Type, Route Of Administration, Indication, Age Group, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，免疫調節藥物市場規模將達到 3,392.8 億美元，年複合成長率為 6.29%。

主要市場統計數據
基準年 2025 2213.4億美元
預計年份：2026年 2348.7億美元
預測年份 2032 3392.8億美元
複合年成長率 (%) 6.29%

免疫調節劑市場是現代專科療法的核心，涵蓋了廣泛的生物製藥、小分子化合物、皮質類固醇、Calcineurin抑制劑、抗代謝物、免疫促效劑、查核點抑制劑、細胞激素調節劑和標靶治療，用於自體免疫疾病、腫瘤學、移植、呼吸道科、胃腸病學、風濕病學、神經病學和發炎等領域。

需求主要受以下因素驅動：全球範圍內免疫介導疾病負擔沉重、癌症免疫療法應用日益廣泛、慢性發炎性疾病治療療程延長，以及TNF、IL、JAK、B細胞、T細胞、補體等標靶機制和共刺激通路調節等技術的持續臨床應用。對於行業領導企業而言，這種成長動能不僅與銷售量提升密切相關，還與實證醫學證據的累積、安全性差異化、生物相似藥策略、患者可及性以及真實世界臨床結果密切相關。

免疫調節藥物領域的變革性變化

免疫調節藥物領域正從廣泛的免疫抑制轉向精準的免疫調節。雖然傳統療法在臨床上仍然重要，但治療流程方案越來越重視標靶生物製劑、口服小分子生技藥品和聯合治療，這些療法能夠在提高療效的同時，控制感染風險、惡性腫瘤徵兆、心血管徵兆、實驗室監測需求以及治療的連續性。

人工智慧的累積影響

人工智慧正在對免疫調節藥物的發現、開發、商業化和上市後監測的各個階段產生累積影響。機器學習模型正被用於識別免疫通路、確定標靶優先順序、篩檢分子、分析多組體學數據、改進臨床試驗以及從真實世界數據源中檢測不利事件模式。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

由於美國和加拿大積極使用專科藥物、擁有先進的生物製藥基礎設施、活躍的臨床試驗活動以及創新療法的快速普及，北美仍然是一個高價值的免疫調節劑市場。歐洲受益於完善的監管流程、廣泛的專科醫療網路以及生物相似藥的廣泛應用，但價格談判和衛生技術評估 (HTA) 的要求會影響產品上市順序和報銷決策。

關鍵集團洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協，隨著醫療體係不斷完善，提高專科藥物的可及性，免疫調節劑作為成長點的重要性日益凸顯，但報銷機制的差異、診斷能力的參差不齊以及生物製藥價格的波動仍然是重要的障礙。在海灣合作理事會國家，先進的醫療基礎設施、癌症治療、移植能力以及專科藥物的需求，使得創新免疫調節劑和品質有保證的生物類似藥的需求都居高不下。

來自主要免疫調節藥物市場關鍵國家的見解

美國在免疫調節創新、專科藥房的使用、臨床試驗活動以及生物製藥的上市方面處於主導。而加拿大則強調實證報銷、真實世界價值和全國的可及性。墨西哥和巴西是拉丁美洲的關鍵市場，公共部門採購、私人專科醫療、生物相似藥之間的競爭以及確保價格可負擔性的項目正在推動生物製藥和免疫抑制療法的普及。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化的作用機制、生物標記驅動的研發以及能夠證明持續緩解、降低類固醇依賴性、減少住院負擔、提高用藥依從性和改善生活品質的真實世界證據項目。此外，隨著支付方主導的轉換、競標和處方藥清單管理持續影響生物製藥領域，各企業必須制定針對生物相似藥的防禦和參與策略。

調查方法

本執行摘要基於系統的二級研究方法，包括對監管批准、臨床開發趨勢、治療指南、支付方趨勢、競爭定位、當地醫療保健基礎設施、藥物安全研究途徑要求以及公開的科學和政策資訊來源的分析。

結論

免疫調節藥物正從特殊療法發展成為精準醫療的基石。推動這一市場發展的因素包括慢性免疫介導疾病的負擔、癌症免疫療法的擴展、移植醫學的發展、生物相似藥的普及以及對標靶免疫通路研究的持續投入。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 免疫調節劑市場：依產品類型分類

  • 細胞激素和干擾素
  • 單株抗體
    • 嵌合體
    • 完全人類
    • 人性化
    • 小鼠來源
  • 低分子化合物
  • 疫苗

第8章：免疫調節劑市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下
  • 外用

第9章：免疫調節劑市場：依適應症分類

  • 癌症
  • 發炎性腸道疾病
  • 多發性硬化症
  • 銀屑病
  • 類風濕性關節炎

第10章 免疫調節劑市場：依年齡層別分類

  • 兒童
  • 成人
  • 老年人

第11章 免疫調節劑市場：依通路分類

  • 線上
  • 離線

第12章 免疫調節劑市場：依最終用戶分類

  • 醫院
  • 零售藥房
  • 專科診所

第13章 免疫調節劑市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 免疫調節劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 免疫調節劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • aTyr Pharma, Inc.
  • BioNTech SE
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Glenmark Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-ED54C46E814C

The Immunomodulators Market is projected to grow by USD 339.28 billion at a CAGR of 6.29% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 221.34 billion
Estimated Year [2026] USD 234.87 billion
Forecast Year [2032] USD 339.28 billion
CAGR (%) 6.29%

The immunomodulators market sits at the center of modern specialty therapeutics, spanning biologics, small molecules, corticosteroids, calcineurin inhibitors, antimetabolites, immunostimulants, checkpoint inhibitors, cytokine modulators, and targeted therapies used across autoimmune disease, oncology, transplantation, dermatology, gastroenterology, rheumatology, neurology, and respiratory inflammation.

Demand is supported by the well-documented global burden of immune-mediated disorders, expanding cancer immunotherapy use, longer treatment duration in chronic inflammatory diseases, and ongoing clinical adoption of targeted mechanisms such as TNF, IL, JAK, B-cell, T-cell, complement, and costimulation pathway modulation. For industry leaders, momentum is increasingly tied to evidence generation, safety differentiation, biosimilar strategy, patient access, and real-world outcomes rather than volume expansion alone.

Transformative Shifts in the Immunomodulators Landscape

The immunomodulators landscape is shifting from broad immune suppression toward precision immune regulation. Legacy therapies remain clinically relevant, but treatment algorithms increasingly prioritize targeted biologics, oral small molecules, and combination strategies that can improve efficacy while managing infection risk, malignancy warnings, cardiovascular signals, laboratory monitoring needs, and treatment persistence.

Another structural shift is the rise of biosimilars and value-based contracting. As major biologics lose exclusivity, payers are using formulary design, tendering, and switching policies to reduce costs, while innovators are investing in next-generation assets, new delivery formats, longer-acting formulations, and biomarker-defined patient populations. The competitive advantage is moving toward products that demonstrate durable remission, convenient administration, strong safety surveillance, and clear health-economic value.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across immunomodulator discovery, development, commercialization, and post-market monitoring. Machine learning models are being used to identify immune pathways, prioritize targets, screen molecules, analyze multi-omics data, enrich clinical trials, and detect adverse-event patterns from real-world evidence sources.

AI is also improving operational performance through trial site selection, patient matching, pharmacovigilance automation, supply planning, and medical affairs intelligence. The greatest impact is expected where AI is paired with high-quality longitudinal clinical data, validated biomarkers, and transparent governance, because immunomodulators require precise benefit-risk assessment across heterogeneous patient populations.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

North America remains a high-value immunomodulators region due to strong specialty drug utilization, advanced biologics infrastructure, high clinical trial activity, and rapid uptake of innovative therapies in the United States and Canada. Europe benefits from established regulatory pathways, broad specialty care networks, and biosimilar adoption, while pricing negotiations and health technology assessment requirements shape launch sequencing and reimbursement decisions.

Asia-Pacific is expanding as China, Japan, India, South Korea, Australia, and ASEAN markets improve diagnosis, reimbursement, local manufacturing, and clinical research participation. Latin America, led by Brazil and Mexico, shows growing demand for autoimmune, oncology, and transplant immunomodulators but remains constrained by affordability, access inequality, and public procurement dynamics. The Middle East, particularly GCC countries, is investing in tertiary care, oncology centers, transplant programs, and specialty medicine access, while Africa's opportunity is tied to improved diagnostics, cold-chain capacity, healthcare workforce development, and broader access to essential immunosuppressive and biologic therapies.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN is becoming a more relevant immunomodulators growth cluster as healthcare systems strengthen specialty care access, although reimbursement fragmentation, uneven diagnostic capacity, and variable biologic affordability remain important barriers. GCC countries are prioritizing advanced care infrastructure, oncology treatment, transplantation capabilities, and specialty pharmaceuticals, supporting demand for both innovative immunomodulators and quality-assured biosimilars.

The European Union continues to influence global standards through centralized approvals, pharmacovigilance rigor, biosimilar confidence, and health technology assessment discipline. BRICS markets combine large patient pools with expanding domestic manufacturing, public health priorities, and policy support for local innovation. G7 markets represent the highest concentration of premium specialty drug spending, clinical evidence generation, and early adoption of targeted therapies, while NATO countries overlap significantly with high-income systems where supply resilience, medicine security, cold-chain continuity, and regulatory alignment are strategic priorities.

Key Country Insights Across Major Immunomodulator Markets

The United States leads in immunomodulator innovation, specialty pharmacy utilization, clinical trial activity, and biologic launches, while Canada emphasizes evidence-based reimbursement, real-world value, and pan-Canadian access considerations. Mexico and Brazil are important Latin American markets where public-sector procurement, private specialty care, biosimilar competition, and affordability programs shape adoption of biologics and immunosuppressive therapies.

In Europe, the United Kingdom, Germany, France, Italy, and Spain remain core markets for autoimmune and oncology immunomodulators, with Germany offering early launch access and other markets emphasizing negotiated value, guideline alignment, and health technology assessment. Russia retains demand for immunosuppressive and biologic therapies but faces procurement, reimbursement, and supply constraints. China is accelerating local biologic development, oncology immunotherapy adoption, and regulatory modernization; India is important for biosimilars, cost-effective access, and domestic manufacturing; Japan and South Korea remain advanced markets with strong regulatory quality, aging-population demand, and specialty care infrastructure; and Australia combines high specialty care standards with structured reimbursement evaluation and strong clinical governance.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated mechanisms, biomarker-enabled development, and real-world evidence programs that demonstrate sustained remission, reduced steroid dependence, lower hospitalization burden, improved adherence, and better quality of life. Organizations should also build biosimilar defense and participation strategies, because payer-driven switching, tendering, and formulary management will continue to influence biologic categories.

Commercial success will depend on aligning market access, medical education, pharmacovigilance, manufacturing quality, and patient support. Leaders should invest in cold-chain reliability, digital adherence programs, decentralized evidence generation, AI-enabled safety monitoring, and partnerships with regional healthcare systems to expand access without compromising clinical governance.

Research Methodology

This executive summary is built using a structured secondary research approach, including analysis of regulatory approvals, clinical development trends, therapeutic guidelines, payer dynamics, competitive positioning, regional healthcare infrastructure, pharmacovigilance requirements, and publicly available scientific and policy sources.

Market interpretation emphasizes verified industry signals such as biologic and biosimilar adoption, oncology immunotherapy expansion, autoimmune disease treatment pathways, immunosuppressive use in transplantation, and the integration of artificial intelligence in pharmaceutical R&D and pharmacovigilance. Insights are synthesized to support strategic planning and should not replace product-specific regulatory, medical, or reimbursement assessment.

Conclusion

Immunomodulators are evolving from a specialty treatment category into a foundational pillar of precision medicine. The market is supported by chronic immune-mediated disease burden, cancer immunotherapy expansion, transplant medicine, biosimilar penetration, and sustained investment in targeted immune pathways.

The next phase of competition will reward organizations that combine scientific differentiation with access discipline, AI-enabled evidence generation, manufacturing resilience, and patient-centered support. Stakeholders that can prove measurable clinical value across regions and healthcare systems will be best positioned to lead in the global immunomodulators market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Immunomodulators Market, by Product Type

  • 7.1. Cytokines And Interferons
  • 7.2. Monoclonal Antibodies
    • 7.2.1. Chimeric
    • 7.2.2. Fully Human
    • 7.2.3. Humanized
    • 7.2.4. Murine
  • 7.3. Small Molecules
  • 7.4. Vaccines

8. Immunomodulators Market, by Route Of Administration

  • 8.1. Intravenous
  • 8.2. Oral
  • 8.3. Subcutaneous
  • 8.4. Topical

9. Immunomodulators Market, by Indication

  • 9.1. Cancer
  • 9.2. Inflammatory Bowel Disease
  • 9.3. Multiple Sclerosis
  • 9.4. Psoriasis
  • 9.5. Rheumatoid Arthritis

10. Immunomodulators Market, by Age Group

  • 10.1. Pediatric
  • 10.2. Adult
  • 10.3. Geriatric

11. Immunomodulators Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Immunomodulators Market, by End User

  • 12.1. Hospitals
  • 12.2. Retail Pharmacies
  • 12.3. Specialty Clinics

13. Immunomodulators Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Immunomodulators Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Immunomodulators Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Amgen Inc.
  • 17.3. AstraZeneca PLC
  • 17.4. aTyr Pharma, Inc.
  • 17.5. BioNTech SE
  • 17.6. Boehringer Ingelheim GmbH
  • 17.7. Bristol-Myers Squibb Company
  • 17.8. Eli Lilly and Company
  • 17.9. Gilead Sciences, Inc.
  • 17.10. Glenmark Pharmaceuticals, Inc.
  • 17.11. Johnson & Johnson Services, Inc.
  • 17.12. Merck & Co., Inc.
  • 17.13. Novartis AG
  • 17.14. Pfizer Inc.
  • 17.15. Roche Holding AG
  • 17.16. Sanofi S.A.
  • 17.17. Viatris Inc.
  • 17.18. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNOMODULATORS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL IMMUNOMODULATORS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL IMMUNOMODULATORS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL IMMUNOMODULATORS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNOMODULATORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL IMMUNOMODULATORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CYTOKINES AND INTERFERONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CYTOKINES AND INTERFERONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYTOKINES AND INTERFERONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHIMERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHIMERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHIMERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FULLY HUMAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FULLY HUMAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FULLY HUMAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMANIZED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMANIZED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMANIZED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MURINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MURINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MURINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GCC IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 144. GCC IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. GCC IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. GCC IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GCC IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. GCC IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. G7 IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 168. G7 IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. G7 IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. G7 IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. G7 IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. G7 IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. NATO IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 176. NATO IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. NATO IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. NATO IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. NATO IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. NATO IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. CANADA IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. CANADA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. CANADA IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 193. CANADA IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. CANADA IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. CANADA IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. CANADA IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. CANADA IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. MEXICO IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. MEXICO IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. MEXICO IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 201. MEXICO IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. MEXICO IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. MEXICO IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. MEXICO IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. MEXICO IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. BRAZIL IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. BRAZIL IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. BRAZIL IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 209. BRAZIL IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRAZIL IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 211. BRAZIL IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. BRAZIL IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. BRAZIL IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED KINGDOM IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED KINGDOM IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED KINGDOM IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED KINGDOM IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED KINGDOM IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED KINGDOM IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED KINGDOM IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED KINGDOM IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GERMANY IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. GERMANY IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. GERMANY IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 225. GERMANY IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. GERMANY IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 227. GERMANY IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. GERMANY IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. GERMANY IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. FRANCE IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. FRANCE IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. FRANCE IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 233. FRANCE IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. FRANCE IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. FRANCE IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. FRANCE IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. FRANCE IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. RUSSIA IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. RUSSIA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. RUSSIA IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 241. RUSSIA IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. RUSSIA IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 243. RUSSIA IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. RUSSIA IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. RUSSIA IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. ITALY IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. ITALY IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. ITALY IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 249. ITALY IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. ITALY IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. ITALY IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. ITALY IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. ITALY IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. SPAIN IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. SPAIN IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. SPAIN IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 257. SPAIN IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. SPAIN IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. SPAIN IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. SPAIN IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. SPAIN IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. INDIA IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. INDIA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. INDIA IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 273. INDIA IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. INDIA IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. INDIA IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. INDIA IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. INDIA IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. JAPAN IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. JAPAN IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. JAPAN IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 281. JAPAN IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. JAPAN IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 283. JAPAN IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. JAPAN IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. JAPAN IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. AUSTRALIA IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. AUSTRALIA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. AUSTRALIA IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 289. AUSTRALIA IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. AUSTRALIA IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 291. AUSTRALIA IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 292. AUSTRALIA IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. AUSTRALIA IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. SOUTH KOREA IMMUNOMODULATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. SOUTH KOREA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. SOUTH KOREA IMMUNOMODULATORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 297. SOUTH KOREA IMMUNOMODULATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 298. SOUTH KOREA IMMUNOMODULATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 299. SOUTH KOREA IMMUNOMODULATORS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 300. SOUTH KOREA IMMUNOMODULATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. SOUTH KOREA IMMUNOMODULATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)